Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-label Extension Study of Chronocort in Congenital Adrenal Hyperplasia
2021-004467-26Phase 3Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydrocortisone modified-release in 21-hydroxylase deficiency (21-OHD), sponsored by Neurocrine Biosciences. Primary endpoint: Long-term safety of Chronocort. Started Dec 2021; status: completed.
02
Drugs
hydrocortisone modified-release
03
Conditions
21-hydroxylase deficiency (21-OHD)
Beyond the preview
Go deeper on 2021-004467-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004467-26.